GSK Paxil Patent Delistings Open Door For Generic Paroxetine Approvals

GlaxoSmithKline's delisting of three Paxil patents will clear the way for approval of generic versions of the antidepressant, and set up a potential dispute over how 180-day exclusivity will be awarded